CSP
1 min read
13

#24-446 Listing of Derivatives at NGM

December 30, 2024
0

Reading Time: < 1 minute Information about various derivatives that will be listed at NGM. For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGM Nordic Growth Market

Continue Reading
CSP
1 min read
13

#24-447 Delisting of Derivatives from NGM

December 30, 2024
0

Reading Time: < 1 minute Information about certain derivatives that will be delisted from NGM. For more details, see attached files. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGM Nordic Growth Market

Continue Reading
CSP
4 min read
11

Vestas wins order for 270 MW project in the USA developed by Steelhead Americas, Vestas’ North American development arm

December 30, 2024
0

Reading Time: 3 minutes News release from Vestas–American Wind TechnologyPortland, 30 December, 2024 Vestas has received a 270 MW order to power an undisclosed wind project in the USA. The order consists of 60 V163-4.5 MW turbines, Vestas’ newest high-capacity factor turbine and the project has

Continue Reading
Change of number of shares and votes in MilDef Group AB (publ)
CSP
2 min read
10

Change of number of shares and votes in MilDef Group AB (publ)

December 30, 2024
0

Reading Time: 2 minutes Pursuant to the Swedish Financial Instruments Trading Act (Sw. lagen (1991:980) om handel med finansiella instrument), Swedish companies whose shares are listed on a regulated market and that are increasing or reducing the total number of shares or votes in the

Continue Reading
CSP
1 min read
12

ALEXANDRIA GROUP OYJ: ACQUISITION OF OWN SHARES 30.12.2024

December 30, 2024
0

Reading Time: < 1 minute   ALEXANDRIA GROUP OYJ NOTIFICATION     30.12.2024 at 18:30 EET   ALEXANDRIA GROUP OYJ: ACQUISITION OF OWN SHARES 30.12.2024   Date 30.12.2024   Exchange transaction Buy   Share class ALEX   Amount 25   Average price/share 8.8500 EUR Highest

Continue Reading
CSP
15 min read
10

Eevia Health Plc plans to arrange a rights issue having maximum amount of approximately SEK 12.1 million to finance its strategic reorientation and turnaround plan

December 30, 2024
0

Reading Time: 11 minutes The Board of Directors of Eevia Health Plc (“Eevia” or the “Company”) has today decided on its intention to execute a rights issue of shares, with preferential rights for the Company’s existing shareholders, having maximum amount of approximately SEK 12.1 before deduction

Continue Reading
CSP
7 min read
7

Notice to the Extraordinary General Meeting of Eevia Health Abp

December 30, 2024
0

Reading Time: 5 minutes Notice is given to the shareholders of Eevia Health Abp (Plc) to the Extraordinary General Meeting to be held on 17 January 2025 at 12:00 (Finnish time GMT +3) at the main office of Eevia Health Abp in Koulukatu 14, Seinäjoki, Finland.

Continue Reading
CSP
2 min read
39

Buybacks of shares by Scandic during week 52, 2024

December 30, 2024
0

Reading Time: 2 minutes Between 23 December 2024 and 27 December 2024, Scandic Hotels Group AB (publ) (LEI: 529900JY9ZBGUXGRKQ86) has repurchased in total 142,060 own shares (ISIN: SE0007640156) as part of the share buyback program initiated by the Board of Directors. The buybacks form part

Continue Reading
CSP
3 min read
10

Dataloy Caps Off 2024 with Record Growth and Q4 Innovations Driving Maritime Excellence

December 30, 2024
0

Reading Time: 2 minutes Closing 2024 with close to 25% revenue growth, including a strong fourth quarter, Dataloy Systems continues to strengthen its position in maritime digitalisation. Bergen, Norway – 30 December 2024 – Dataloy Systems, a global leader in voyage management solutions, concludes 2024 on

Continue Reading
Immedica to acquire biopharmaceutical company Marinus Pharmaceuticals, Inc.
CSP
11 min read
10

Immedica to acquire biopharmaceutical company Marinus Pharmaceuticals, Inc.

December 30, 2024
0

Reading Time: 7 minutes Stockholm, Sweden and Radnor, Pa. – December 30, 2024 – Immedica Pharma AB (Immedica), a leading global rare disease company, and Marinus Pharmaceuticals, Inc. (Nasdaq:  MRNS), a pharmaceutical company committed to improving the lives of patients with seizure disorders, today

Continue Reading